Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
21.20
-0.20 (-0.93%)
Feb 11, 2026, 5:35 PM CET
Market Cap853.60M +19.0%
Revenue (ttm)84.66M +2,060.3%
Net Income45.91M
EPS1.14
Shares Out40.26M
PE Ratio18.55
Forward PE5.40
Dividendn/a
Ex-Dividend Daten/a
Volume5,815
Average Volume15,824
Open21.50
Previous Close21.40
Day's Range21.20 - 21.50
52-Week Range17.40 - 27.80
Beta0.09
RSI45.81
Earnings DateMar 27, 2026

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 201
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements